Targeting MYC in cancer therapy: RNA processing offers new opportunities

BioEssays

Volumn 38, Issue 3, 2016, Pages 266-275

  Koh, Cheryl M ^a   Sabò, Arianna ^b   Guccione, Ernesto ^a,c,d  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Cancer therapy; MYC; Post transcriptional regulation; RNA; Splicing; Synthetic lethality; Transcription

Indexed keywords

CANCER THERAPY; GENE EXPRESSION; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; ONCOGENE MYC; RNA PROCESSING; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY;

ANTINEOPLASTIC AGENT; MESSENGER RNA; MYC PROTEIN; MYC PROTEIN, HUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER;

EID: 84968343089     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201500134     Document Type: Article

References (125)

1. Gabay M, Li Y, Felsher DW. 2014. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 4: pii: a014241.
2. Blackwood EM, Eisenman RN. 1991. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-7.
3. Amati B, Brooks MW, Levy N, Littlewood TD, et al. 1993. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72: 233-45.
4. Guccione E, Martinato F, Finocchiaro G, Luzi L, et al. 2006. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 8: 764-70.
5. Kress TR, Sabo A, Amati B. 2015. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 15: 593-607.
6. Gomez-Roman N, Felton-Edkins ZA, Kenneth NS, Goodfellow SJ, et al. 2006. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochem Soc Symp 2006: 141-54.
7. Lin CY, Loven J, Rahl PB, Paranal RM, et al. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
8. Nie Z, Hu G, Wei G, Cui K, et al. 2012. C-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
9. Sabo A, Kress TR, Pelizzola M, de Pretis S, et al. 2014. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511: 488-92.
10. Gonatopoulos-Pournatzis T, Cowling VH. 2014. Cap-binding complex (CBC). Biochem J 457: 231-42.
11. Montanaro L, Pandolfi PP. 2004. Initiation of mRNA translation in oncogenesis: the role of eIF4E. Cell Cycle 3: 1387-9.
12. Cole MD, Cowling VH. 2009. Specific regulation of mRNA cap methylation by the c-Myc and E2F1 transcription factors. Oncogene 28: 1169-75.
13. Cowling VH, Cole MD. 2007. The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol 27: 2059-73.
14. Fernandez-Sanchez ME, Gonatopoulos-Pournatzis T, Preston G, Lawlor MA, et al. 2009. S-adenosyl homocysteine hydrolase is required for Myc-induced mRNA cap methylation, protein synthesis, and cell proliferation. Mol Cell Biol 29: 6182-91.
15. Braunstein S, Karpisheva K, Pola C, Goldberg J, et al. 2007. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28: 501-12.
16. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, et al. 2013. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci USA 110: 11988-93.
17. Biamonti G, Bassi MT, Cartegni L, Mechta F, et al. 1993. Human hnRNP protein A1 gene expression. Structural and functional characterization of the promoter. J Mol Biol 230: 77-89.
18. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, et al. 2008. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-3.
19. David CJ, Chen M, Assanah M, Canoll P, et al. 2010. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-8.
20. Nadiminty N, Tummala R, Liu C, Lou W, et al. 2015. NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther 14: 1884-95.
21. Rauch J, Moran-Jones K, Albrecht V, Schwarzl T, et al. 2011. C-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway. Cancer Res 71: 4664-74.
22. Das S, Anczukow O, Akerman M, Krainer AR. 2012. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 1: 110-7.
23. Anczukow O, Rosenberg AZ, Akerman M, Das S, et al. 2012. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19: 220-8.
24. Das S, Krainer AR. 2014. Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer. Mol Cancer Res 12: 1195-204.
25. Hirsch CL, Coban Akdemir Z, Wang L, Jayakumaran G, et al. 2015. Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming. Genes Dev 29: 803-16.
26. Wu CY, Tsai YP, Wu MZ, Teng SC, et al. 2012. Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends Genet 28: 454-63.
27. Cowling VH, Cole MD. 2007. E-cadherin repression contributes to c-Myc-induced epithelial cell transformation. Oncogene 26: 3582-6.
28. Cho MH, Park JH, Choi HJ, Park MK, et al. 2015. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat Commun 6: 7821.
29. Koh CM, Bezzi M, Low DH, Ang WX, et al. 2015. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523: 96-100.
30. Hsu TY, Simon LM, Neill NJ, Marcotte R, et al. 2015. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525: 384-8.
31. Hubert CG, Bradley RK, Ding Y, Toledo CM, et al. 2013. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev 27: 1032-45.
32. Gruber AR, Fallmann J, Kratochvill F, Kovarik P, et al. 2011. AREsite: a database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res 39: D66-9.
33. Rounbehler RJ, Fallahi M, Yang C, Steeves MA, et al. 2012. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell 150: 563-74.
34. Mukherjee N, Jacobs NC, Hafner M, Kennington EA, et al. 2014. Global target mRNA specification and regulation by the RNA-binding protein Z FP36. Genome Biol 15: R12.
35. Zhang J, Tsaprailis G, Bowden GT. 2008. Nucleolin stabilizes Bcl-X L messenger RNA in response to UVA irradiation. Cancer Res 68: 1046-54.
36. Kelly PN, Grabow S, Delbridge AR, Strasser A, et al. 2011. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 118: 6380-6.
37. Lareau LF, Inada M, Green RE, Wengrod JC, et al. 2007. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 446: 926-9.
38. Ni JZ, Grate L, Donohue JP, Preston C, et al. 2007. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev 21: 708-18.
39. Karam R, Lou CH, Kroeger H, Huang L, et al. 2015. The unfolded protein response is shaped by the NMD pathway. EMBO Rep 16: 599-609.
40. Gardner LB. 2008. Hypoxic inhibition of nonsense-mediated RNA decay regulates gene expression and the integrated stress response. Mol Cell Biol 28: 3729-41.
41. Popp MW, Maquat LE. 2013. Organizing principles of mammalian nonsense-mediated mRNA decay. Annu Rev Genet 47: 139-65.
42. Wang D, Wengrod J, Gardner LB. 2011. Overexpression of the c-myc oncogene inhibits nonsense-mediated RNA decay in B lymphocytes. J Biol Chem 286: 40038-43.
43. Shao A, Wilkinson MF. 2014. Suppressing nonsense-a surprising function for 5-azacytidine. EMBO Mol Med 6: 1518-20.
44. Chang TC, Yu D, Lee YS, Wentzel EA, et al. 2008. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50.
45. Bruno IG, Karam R, Huang L, Bhardwaj A, et al. 2011. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol Cell 42: 500-10.
46. Januszyk K, Lima CD. 2014. The eukaryotic RNA exosome. Curr Opin Struct Biol 24: 132-40.
47. Chen CY, Gherzi R, Ong SE, Chan EL, et al. 2001. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 107: 451-64.
48. Perna D, Faga G, Verrecchia A, Gorski MM, et al. 2012. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene 31: 1695-709.
49. Iritani BM, Eisenman RN. 1999. C-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 96: 13180-5.
50. Arabi A, Wu S, Ridderstrale K, Bierhoff H, et al. 2005. C-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7: 303-10.
51. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, et al. 2005. C-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7: 311-8.
52. Grewal SS, Li L, Orian A, Eisenman RN, et al. 2005. Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development. Nat Cell Biol 7: 295-302.
53. Poortinga G, Hannan KM, Snelling H, Walkley CR, et al. 2004. MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J 23: 3325-35.
54. Gomez-Roman N, Grandori C, Eisenman RN, White RJ. 2003. Direct activation of RNA polymerase III transcription by c-Myc. Nature 421: 290-4.
55. Kenneth NS, Ramsbottom BA, Gomez-Roman N, Marshall L, et al. 2007. TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc Natl Acad Sci USA 104: 14917-22.
56. Filipowicz W, Pogacic V. 2002. Biogenesis of small nucleolar ribonucleoproteins. Curr Opin Cell Biol 14: 319-27.
57. Herter EK, Stauch M, Gallant M, Wolf E, et al. 2015. SnoRNAs are a novel class of biologically relevant Myc targets. BMC Biol 13: 25.
58. Ji H, Wu G, Zhan X, Nolan A, et al. 2011. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS ONE 6: e26057.
59. Rosenwald IB, Rhoads DB, Callanan LD, Isselbacher KJ, et al. 1993. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci USA 90: 6175-8.
60. Jones RM, Branda J, Johnston KA, Polymenis M, et al. 1996. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 16: 4754-64.
61. Psathas JN, Thomas-Tikhonenko A. 2014. MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med 4: pii: a014175.
62. Deng K, Guo X, Wang H, Xia J. 2014. The lncRNA-MYC regulatory network in cancer. Tumour Biol 35: 9497-503.
63. Frenzel A, Loven J, Henriksson MA. 2010. Targeting MYC-Regulated miRNAs to Combat Cancer. Genes Cancer 1: 660-7.
64. Ma MZ, Li CX, Zhang Y, Weng MZ, et al. 2014. Long non-coding RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer. Mol Cancer 13: 156.
65. Wang T, Wang G, Hao D, Liu X, et al. 2015. Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. Mol Cancer 14: 125.
66. Wang X, Zhao X, Gao P, Wu M. 2013. C-Myc modulates microRNA processing via the transcriptional regulation of Drosha. Sci Rep 3.
67. Levens D. 2008. How the c-myc promoter works and why it sometimes does not. J Natl Cancer Inst Monogr 2008: 41-3.
68. Hnisz D, Abraham BJ, Lee TI, Lau A, et al. 2013. Super-enhancers in the control of cell identity and disease. Cell 155: 934-47.
69. Zuber J, Shi J, Wang E, Rappaport AR, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-8.
70. Mertz JA, Conery AR, Bryant BM, Sandy P, et al. 2011. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108: 16669-74.
71. Delmore JE, Issa GC, Lemieux ME, Rahl PB, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-17.
72. Fowler T, Ghatak P, Price DH, Conaway R, et al. 2014. Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. PLoS ONE 9: e87003.
73. Filippakopoulos P, Knapp S. 2014. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13: 337-56.
74. Brown RV, Danford FL, Gokhale V, Hurley LH, et al. 2011. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem 286: 41018-27.
75. Ou TM, Lu YJ, Zhang C, Huang ZS, et al. 2007. Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem 50: 1465-74.
76. Weidensdorfer D, Stohr N, Baude A, Lederer M, et al. 2009. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA 15: 104-15.
77. Liu L, Ouyang M, Rao JN, Zou T, et al. 2015. Competition between RNA-binding proteins CELF1 and HuR modulates MYC translation and intestinal epithelium renewal. Mol Biol Cell 26: 1797-810.
78. Shi Y, Yang Y, Hoang B, Bardeleben C, et al. 2015. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene, in press. DOI: 10.1038/onc.2015.156.
79. Nilsson JA, Keller UB, Baudino TA, Yang C, et al. 2005. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7: 433-44.
80. Forshell TP, Rimpi S, Nilsson JA. 2010. Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. Cancer Prev Res 3: 140-7.
81. Nanbru C, Lafon I, Audigier S, Gensac MC, et al. 1997. Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site. J Biol Chem 272: 32061-6.
82. Wiegering A, Uthe FW, Jamieson T, Ruoss Y, et al. 2015. Targeting translation initiation bypasses signaling crosstalk mechanisms that maintain high MYC levels in colorectal cancer. Cancer Discov 5: 768-81.
83. Farrell AS, Sears RC. 2014. MYC degradation. Cold Spring Harb Perspect Med 4: pii: a014365.
84. Balaji KC, Koul H, Mitra S, Maramag C, et al. 1997. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology 50: 1007-15.
85. Iversen PL, Arora V, Acker AJ, Mason DH, et al. 2003. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 9: 2510-9.
86. Sekhon HS, London CA, Sekhon M, Iversen PL, et al. 2008. C-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer 60: 347-54.
87. Giles RV, Spiller DG, Clark RE, Tidd DM. 1999. Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev 9: 213-20.
88. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, et al. 1998. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17: 2463-72.
89. Savino M, Annibali D, Carucci N, Favuzzi E, et al. 2011. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS ONE 6: e22284.
90. Soucek L, Jucker R, Panacchia L, Ricordy R, et al. 2002. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62: 3507-10.
91. Soucek L, Whitfield J, Martins CP, Finch AJ, et al. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455: 679-83.
92. Berg T. 2011. Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Topics Microbiol Immunol 348: 139-49.
93. Jung KY, Wang H, Teriete P, Yap JL, et al. 2015. Perturbation of the c-Myc-Max protein-protein interaction via synthetic alpha-helix mimetics. J Med Chem 58: 3002-24.
94. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, et al. 2007. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104: 7391-6.
95. Heffern MC, Kurutz JW, Meade TJ. 2013. Spectroscopic elucidation of the inhibitory mechanism of Cys2His2 zinc finger transcription factors by cobalt(III) Schiff base complexes. Chemistry 19: 17043-53.
96. McLornan DP, List A, Mufti GJ. 2014. Applying synthetic lethality for the selective targeting of cancer. New Engl J Med 371: 1725-35.
97. Cermelli S, Jang IS, Bernard B, Grandori C. 2014. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4: pii: a014209.
98. Toyoshima M, Howie HL, Imakura M, Walsh RM, et al. 2012. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 109: 9545-50.
99. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, et al. 2014. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 28: 1800-14.
100. Kessler JD, Kahle KT, Sun T, Meerbrey KL, et al. 2012. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335: 348-53.
101. Zhou Z, Patel M, Ng N, Hsieh MH, et al. 2014. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening. BMC Cancer 14: 944.
102. Liu L, Ulbrich J, Muller J, Wustefeld T, et al. 2012. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 483: 608-12.
103. Rottmann S, Wang Y, Nasoff M, Deveraux QL, et al. 2005. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci USA 102: 15195-200.
104. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, et al. 2011. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 18: 1331-5.
105. Hoglund A, Nilsson LM, Forshell LP, Maclean KH, et al. 2009. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 113: 4281-8.
106. den Hollander J, Rimpi S, Doherty JR, Rudelius M, et al. 2010. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116: 1498-505.
107. Hook KE, Garza SJ, Lira ME, Ching KA, et al. 2012. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Therapeut 11: 710-9.
108. Diaz RJ, Golbourn B, Faria C, Picard D, et al. 2015. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget 6: 3359-74.
109. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, et al. 2012. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 209: 679-96.
110. Goga A, Yang D, Tward AD, Morgan DO, et al. 2007. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 13: 820-7.
111. Campaner S, Doni M, Hydbring P, Verrecchia A, et al. 2010. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 12: 1-4.
112. Wang Y, Engels IH, Knee DA, Nasoff M, et al. 2004. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5: 501-12.
113. Wang J, Anderson PD, Luo W, Gius D, et al. 2012. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene 31: 1794-803.
114. Kirschner AN, Wang J, van der Meer R, Anderson PD, et al. 2015. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Instit 107: pii: dju407.
115. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
116. Wall M, Poortinga G, Stanley KL, Lindemann RK, et al. 2013. The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov 3: 82-95.
117. Lin CJ, Nasr Z, Premsrirut PK, Porco JA, Jr., et al. 2012. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep 1: 325-33.
118. Lim JH, Lee YM, Lee G, Choi YJ, et al. 2014. PRMT5 is essential for the eIF4E-mediated 5'-cap dependent translation. Biochem Biophys Res Commun 452: 1016-21.
119. Miluzio A, Beugnet A, Grosso S, Brina D, et al. 2011. Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell 19: 765-75.
120. Barna M, Pusic A, Zollo O, Costa M, et al. 2008. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456: 971-5.
121. Bywater MJ, Poortinga G, Sanij E, Hein N, et al. 2012. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22: 51-65.
122. Negi SS, Brown P. 2015. RRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis. Oncotarget 6: 18094-104.
123. Hua Y, Vickers TA, Okunola HL, Bennett CF, et al. 2008. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82: 834-48.
124. Comiskey DF, Jr., Jacob AG, Singh RK, Tapia-Santos AS, et al. 2015. Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage. Nucleic Acids Res 43: 4202-18.
125. Bonnal S, Vigevani L, Valcarcel J. 2012. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11: 847-59.